5-bromo-1-(pyridin-2-yl)-1H-indazole | 504424-75-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-bromo-1-(pyridin-2-yl)-1H-indazole
• 英文别名: 5-Bromo-1-(2-pyridyl)-1H-indazole；5-bromo-1-pyridin-2-ylindazole
• CAS: 504424-75-3
• 化学式: C₁₂H₈BrN₃
• 分子量: 274.12
• InChiKey: GZHMGISVFCQZPX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  30.7
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-碘吡啶 、 5-溴吲唑 在 copper(I) oxide 、 caesium carbonate 作用下， 以 二甲基亚砜 为溶剂， 反应 24.0h， 以76%的产率得到5-bromo-1-(pyridin-2-yl)-1H-indazole
  参考文献：
  名称：

  无配体的Cu 2 O催化的氮杂环与碘吡啶的交叉偶联

  摘要：

  已经开发了一种实用且有效的策略，用于使用无配体的Cu 2 O作为催化剂和Cs 2 CO 3作为碱将氮杂环与卤代吡啶交叉偶联。该方案适用于一系列高度官能化的杂环，例如7-氮杂吲哚，吲唑，吲哚，咪唑，吡咯和吡唑，可提供高收率的N-杂芳基衍生物（最高96％）。

  DOI：

  10.1016/j.tet.2013.06.095

文献信息

• Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors
  申请人：——

  公开号：US20040236110A1

  公开（公告）日：2004-11-25

  The invention provides novel substituted 3-pyridyl indoles and indazoles and pharmaceutical compositions thereof. The invention also provides methods of use of substituted 3-pyridyl indoles and indazoles and pharmaceutical compositions thereof as inhibitors of lyases, e.g., the 17&agr;-hydroxylase-C17,20-lyase enzyme. The invention further provides methods for the treatment of cancer in a subject, comprising administering a substituted 3-pyridyl indoles and indazoles or a pharmaceutical composition comprising a substituted 3-pyridyl indoles and indazoles to a subject. The cancer can be, e.g., prostate cancer or breast cancer.

  本发明提供了新型的取代的3-吡啶基吲哚和吲唑以及其制药组合物。本发明还提供了使用取代的3-吡啶基吲哚和吲唑以及其制药组合物作为裂解酶抑制剂（例如17α-羟基化酶-C17,20-裂解酶酶）的方法。本发明还提供了治疗受试者癌症的方法，包括向受试者施用取代的3-吡啶基吲哚和吲唑或包含取代的3-吡啶基吲哚和吲唑的制药组合物。癌症可以是前列腺癌或乳腺癌。
• Manganese-Mediated N-Heteroarylation of Indoles and Indazoles in Water
  作者：Yong-Chua Teo、Fui-Fong Yong

  DOI：10.1055/s-0032-1316682

  日期：2012.9

  A convenient strategy for the N-heteroarylation of indoles and indazoles using MnF2/trans-1,2-diaminocyclohexane as catalyst and cesium carbonate as the base in water has been developed. The protocol afforded the corresponding N-heteroarylated products in moderate to good yields (up to 90%).
• SUBSTITUTED 3-PYRIDYL INDOLES AND INDAZOLES AS C17,20 LYASE INHIBITORS
  申请人：Bayer Pharmaceuticals Corporation

  公开号：EP1432698A2

  公开（公告）日：2004-06-30
• [EN] SUBSTITUTED 3-PYRIDYL INDOLES AND INDAZOLES AS C17,20 LYASE INHIBITORS<br/>[FR] 3-PYRIDYL INDOLES ET INDAZOLES SUBSTITUES SERVANT D'INHIBITEURS DE C17,20 LYASE
  申请人：BAYER AG

  公开号：WO2003027094A2

  公开（公告）日：2003-04-03

  The invention provides novel substituted 3-pyridyl indoles and indazoles and pharmaceutical compositions thereof. The invention also provides methods of use of substituted 3-pyridyl indoles and indazoles and pharmaceutical compositions thereof as inhibitors of lyases, e.g., the 17α-hydroxylase-C17,20-lyase enzyme. The invention further provides methods for the treatment of cancer in a subject, comprising administering a substituted 3-pyridyl indoles and indazoles or a pharmaceutical composition comprising a substituted 3-pyridyl indoles and indazoles to a subject. The cancer can be, e.g., prostate cancer or breast cancer.